Recognition of polymyalgia rheumatica is straightforward and it is easily treatable.

"Polymyalgia Rheumatica Pipeline Analysis"DelveInsight's,“Polymyalgia Rheumatica – Pipeline Insight, 2025,” report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in ...

Both polymyalgia rheumatica (PMR) and giant cell arteritis (GCA) present with a broad spectrum of clinical manifestations and almost exclusively occur in the population aged over 50 years. After ...

Therapy for polymyalgia rheumatica (PMR) varies widely in clinical practice as international recommendations for PMR treatment are not currently available. In this paper, we report the 2015 European ...

Polymyalgia rheumatica (PMR) is a systemic inflammatory disorder that predominantly affects individuals over the age of 50. It is characterised by pain and stiffness in the shoulder and hip ...

Home NICE Guidance Conditions and diseases Musculoskeletal conditions Hip conditions Secukinumab for treating relapsed polymyalgia rheumatica [ID6599] Awaiting development [GID-TA11806] Expected ...

Prediction of the Course of PMR & GCA The duration of corticosteroid therapy in PMR is variable. While some patients may discontinue therapy within 1 or 2 years of disease, others have prolonged ...

Patients with relapsing polymyalgia rheumatica have impaired health-related quality of life. The use of sarilumab 200 mg once every 2 weeks with a 14-week glucocorticoid taper led to clinically ...

Find rheumatology news articles, videos, blogs, books, Continuing Medical Education (CME), meeting coverage, and journal articles.

Polymyalgia rheumatica (PMR) is considered to be a benign disease by some, while others think it is a more serious illness which required similar treatment to giant cell arteritis (GCA). The progress ...

The purpose of this extension study is to assess the safety and tolerability of secukinumab when administered long-term in patients with polymyalgia rheumatica. The study will consist of an up to ...